Literature DB >> 14607197

Reference ranges for natriuretic peptides for diagnostic use are dependent on age, gender and heart rate.

Ian Loke1, Iain B Squire, Joan E Davies, Leong L Ng.   

Abstract

BACKGROUND: Plasma natriuretic peptide levels may be useful in the diagnosis of heart failure. The available natriuretic peptide assays differ markedly in their performance characteristics. In addition, plasma levels are influenced by a number of factors including age and gender. AIMS: The aim of this study was to describe, in a healthy population, the influence of clinical and echocardiographic parameters on three natriuretic peptide moieties.
METHODS: 1360 individuals were screened for the presence of left ventricular systolic dysfunction. We identified a cohort (n=720) of men aged 45-80 years (n=417) and women aged 55-80 years (n=303). None had history of cardiovascular disease or were taking any cardiovascular medication. All had normal echocardiographic and ECG findings. B-type (BNP), N-terminal pro-B-type (N-BNP) and N-terminal pro-Atrial (N-ANP) natriuretic peptides were assayed using in-house immunoluminometric assays.
RESULTS: Of the considered clinical variables, only gender and heart rate (each P<0.005) were independently associated with levels of all three natriuretic peptides. Plasma levels of N-ANP (15%), BNP (25%) and N-BNP (75%) were higher in women compared to men. An increase in heart rate of 10 bpm corresponded to a reduction of 9% in N-ANP or BNP and a 15% reduction in N-BNP. Each 10 years of age was associated with 16% and 74% increase in ANP and N-BNP levels, respectively, but no increase in plasma BNP. Left ventricular ejection fraction could be assessed in 582 (81%) subjects and correlated positively with N-ANP (r(s)=6.48x10(-3), P<0.001) and BNP (r(s)=2.4x10(-2), P<0.001) but not N-BNP (P=0.405). No parameter of diastolic function was associated with any peptide level.
CONCLUSIONS: In this healthy population, plasma levels of N-ANP, BNP and N-BNP were variably influenced by clinical covariates. While all three peptides were higher in women, only N-ANP and N-BNP were influenced by age. Levels of all peptides were inversely correlated with heart rate. Using this immunoluminometric assay, plasma BNP is not influenced by age, in contrast to N-ANP and N-BNP. In constructing normal ranges for diagnostic use, covariates such as age and gender must be considered, in addition to the format of assay being used.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14607197     DOI: 10.1016/s1388-9842(03)00108-9

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  28 in total

1.  Safe use of brain natriuretic protein to rule out the diagnosis of heart failure depends on the selection of cut off value.

Authors:  S G Williams; L L Ng; R J O'Brien; D Barker; Y-F Li; L-B Tan
Journal:  Heart       Date:  2005-08       Impact factor: 5.994

2.  Raised plasma N-terminal pro-B-type natriuretic peptide concentrations predict mortality and cardiac disease in end-stage renal disease.

Authors:  R Sharma; D C Gaze; D Pellerin; R L Mehta; H Gregson; C P Streather; P O Collinson; S J D Brecker
Journal:  Heart       Date:  2006-10       Impact factor: 5.994

3.  The Correlation of Serum Brain Natriuretic Peptide and Interleukin-6 with Quality of Life Using the Chronic Obstructive Pulmonary Disease Assessment Test.

Authors:  Hassan Ghobadi; Mohammad Reza Aslani; Adalat Hosseinian; Esmaeil Farzaneh
Journal:  Med Princ Pract       Date:  2017-11-02       Impact factor: 1.927

4.  Which method is best for an early accurate diagnosis of acute heart failure? Comparison between lung ultrasound, chest X-ray and NT pro-BNP performance: a prospective study.

Authors:  Stefano Sartini; Jacopo Frizzi; Matteo Borselli; Elisabetta Sarcoli; Carolina Granai; Veronica Gialli; Gabriele Cevenini; Gianni Guazzi; Fulvio Bruni; Stefano Gonnelli; Marcello Pastorelli
Journal:  Intern Emerg Med       Date:  2016-07-11       Impact factor: 3.397

5.  Relationship of extent and nature of dysfunctional myocardium to brain natriuretic peptide in patients with ischemic left ventricular dysfunction.

Authors:  Charles A Nelson; Colin Case; Jane McCrohon; Thomas H Marwick
Journal:  Int J Cardiovasc Imaging       Date:  2005 Apr-Jun       Impact factor: 2.357

6.  Effects of transdermal testosterone on natriuretic peptide levels in women: a randomized placebo-controlled pilot study.

Authors:  Eleanor Lin; Elizabeth McCabe; Christopher Newton-Cheh; Kenneth Bloch; Emmanuel Buys; Thomas Wang; Karen K Miller
Journal:  Fertil Steril       Date:  2011-12-02       Impact factor: 7.329

7.  Biomarkers of myocardial stress and systemic inflammation in patients who engage in heart failure self-care management.

Authors:  Christopher S Lee; Debra K Moser; Terry A Lennie; Nancy C Tkacs; Kenneth B Margulies; Barbara Riegel
Journal:  J Cardiovasc Nurs       Date:  2011 Jul-Aug       Impact factor: 2.083

8.  B-type natriuretic peptide in reversible myocardial ischaemia.

Authors:  K Chatha; M Alsoud; M J Griffiths; A Elfatih; K Abozguia; R C Horton; S J Dunmore; R Gama
Journal:  J Clin Pathol       Date:  2006-11       Impact factor: 3.411

9.  Prospective evaluation and long-term follow-up of patients referred to secondary care based upon natriuretic peptide levels in primary care.

Authors:  John Gierula; Richard M Cubbon; Maria F Paton; Rowenna Byrom; Judith E Lowry; Sarah F Winsor; Melanie McGinlay; Emma Sunley; Emma Pickles; Lorraine C Kearney; Aaron Koshy; Thomas A Slater; Hemant K Chumun; Haqeel A Jamil; Kristian M Bailey; Julian H Barth; Mark T Kearney; Klaus K Witte
Journal:  Eur Heart J Qual Care Clin Outcomes       Date:  2019-07-01

10.  Plasma midregional pro-atrial natriuretic peptide is associated with blood pressure indices and hypertension severity in adults with hypertension.

Authors:  Mahyar Khaleghi; Umer Saleem; Nils G Morgenthaler; Stephen T Turner; Andreas Bergmann; Joachim Struck; Thomas H Mosley; Iftikhar J Kullo
Journal:  Am J Hypertens       Date:  2009-02-12       Impact factor: 2.689

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.